Friday, February 1, 2013

GSK Initiates Phase 3 study to test combination of BRAF/MEK inhibition in BRAF+ve melanoma patients following surgery

GlaxoSmithKline plc. today announced the start of COMBI-AD, a  Phase III study evaluating the combination of dabrafenib, its BRAF inhibitor and trametinib, its MEK inhibitor as adjuvant therapy for melanoma.  This global study will investigate whether combining the two investigational agents can delay or prevent the recurrence of melanoma (Relapse Free Survival) in patients with Stage IIIa, IIIb, or IIIc BRAF V600E or V600K mutation-positive melanoma that has been completely removed by surgery.  The study will also evaluate the safety profile of the dabrafenib-trametinib combination in this treatment setting.

"The patients included in this trial are at high risk of their melanoma returning after surgery and there are currently few treatment options to reduce this risk" said Dr. Rafael Amado, Head of Oncology R&D for GlaxoSmithKline. "Given the efficacy and safety findings observed with combined dabrafenib-trametinib treatment in the metastatic setting, we are investigating whether the combination administered after surgery can help these patients live longer without melanoma recurrence.”

Two Phase III studies of combined dabrafenib-trametinib are ongoing in the metastatic BRAF V600 melanoma setting. (NCT01584648 and NCT01597908)

COMBI-AD: Study 115532 (NCT01682083) is a Phase III, randomised, double-blinded study comparing the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor, trametinib versus two placebos in the adjuvant treatment of melanoma after surgical resection. Patients with completely resected, histologically confirmed, BRAF V600E/K mutation-positive, high-risk [Stage IIIa (sentinel lymph node metastasis >1 mm), IIIb or IIIc] cutaneous melanoma will be screened for eligibility. Subjects will be randomised to receive either dabrafenib (150mg, twice daily) and trametinib (2mg, once daily) combination therapy or two placebos for 12 months.  The primary endpoint of the study is relapse-free survival.  The study seeks to enrol about 850 subjects from more than 200 investigative sites across the world.

Enter your email address:

Delivered by FeedBurner

No comments:

Post a Comment